세계 두드러기 치료 시장 – 2023-2030

Market Overview
Global Skin Hives Treatment Market reached US$ 2.6 billion in 2022 and is expected to reach US$ 5.7 billion by 2030 growing with a CAGR of 10.5% during the forecast period 2023-2030.
The global skin hives treatment market experiencing significant growth in recent years mainly owing to the increasing prevalence. The skin hives also known as urticaria, the treatment is based on the type of skin hives that is chronic hives and acute hives. According to the Cleveland Clinic organization, around 20% of the population will get hives at least one time. About 1% to 3% of the population has chronic hives.
There are many types of treatments available, including antihistamines, anti-inflammatory drugs, anti-itch drugs, topical anesthetics, topical steroids, immunosuppressants, and others. The most common and effective treatment is antihistamines. Overall, the global market is expected to experience in the coming years.
Owing to the increasing prevalence of skin hives/urticaria, increasing clinical trials and research activities, rising demand for innovative therapeutics, availability of a wide range of treatment options, increasing awareness and early detection, and advancements in the treatment options, among others are the major factors expected to drive the global skin hives market over the forecast period.
Dynamics
Increasing Clinical Trials Drive the Growth of the Skin Hives Treatment Market
There is a continuously increasing clinical trials in the field of skin hives treatment market, which is expected to hold the largest market share over the forecast period. Clinical trials provide informational insights into the underlying mechanisms of skin hives/urticaria and the factors that trigger the condition. This basic knowledge is essential for the development of innovative approaches that address the causes of urticaria.
For instance, on June 21, 2022, Celldex Therapeutics, Inc. announced that the first patient has been dosed in a Phase 2 clinical study of barzolvolimab for the treatment of chronic spontaneous urticaria. Barzolvolimab is a humanized monoclonal antibody that specifically binds the receptor tyrosine kinase KIT with high specificity and potently inhibits its activity.
Clinical trials plays a crucial role by providing a platform for testing novel treatments, including new drugs and therapeutic. Positive results from these trials can lead to regulatory approvals and the introduction of innovative therapies, expanding the range of treatment options available to patients. Clinical trials also helps to address safety and efficacy of the therapeutics.
For instance, on April 10, 2023, Celltrion confirmed the bioequivalence of CT-P39 to treat allergic asthma and chronic urticaria, through its interim results from its global phase 3 clinical trials at 24 weeks. CT-P39 is a biosimilar referencing Xolair, which is an antibody biopharmaceutical that treats allergic asthma, chronic urticaria, and chronic rhinosinusitis.
Rising Regulatory Approvals and Novel Product Launches Also Drive the Growth of the Skin Hives Treatment Market
Regulatory approvals such as FDA approvals signify that the particular treatment has met a safety and efficacy parameters. As a new products receive regulatory approvals, the market gains a wider range of treatment options for better and more effective treatment, allowing healthcare providers to maintain the safety and efficacy of individual patient needs. The regulatory approvals always focus on novel product launches to cover the unmet medical needs.
For instance, on March 7, 2023. The U.S. Food and Drug Administration (FDA) has accepted, for review, the supplemental Biologics License Application for Dupixent (dupilumab) to treat adults and adolescents aged 12 years and older with chronic spontaneous urticaria that is not adequately controlled with the current standard of care, H1 antihistamine treatment. The target action date for the FDA decision is October 22, 2023.
Moreover, the regulatory approvals and product launches can also improves the patient's access to effective treatments. These approvals enhance the innovative treatments meet quality standards and are suitable for the usage of the treatment. And the novel product launches with more effectiveness and lesser side effects results in the better patient outcomes.
Adverse Effects Associated with Drugs Will Hamper the Growth of the Market
There are moderate to severe adverse effects associated with the skin hives drugs, this may be expected to hamper the market growth over the forecast period. If the patients experience adverse effects such as swelling in the face, hands, lymph nodes, and others from a particular drug, there may be a reduced adoption of the drugs due to their side effects. This results in incomplete management of urticaria, leading to inadequate symptom control.
Furthermore, high-profile cases of the severe side effects raise the safety concerns among patients and healthcare providers. This can lead to uncertainty in using certain drugs and medications, even if they are effective, thereby reducing the overall demand for those treatments. Due to the adverse effects, patients also prefer the alternative therapeutics and discontinue the usage of the particular drugs which shows the adverse effects.
Segment Analysis
The global skin hives treatment market is segmented based on type, treatment, route of administration, distribution channel, and region.
The Antihistamines from the Treatment Segment Accounted for Approximately 37.8% of the Skin Hives Treatment Market Share
Antihistamines are the most commonly used therapeutics for the treatment of skin hives or urticaria and holds the largest market share over the forecast period. They are very effective in providing relief from itching for patients with urticaria and reducing the symptoms of skin hives for many individuals. They are often considered a first-line treatment for patients who are suffering from acute urticaria. Many ongoing clinical trials, research activities, and regulatory approvals provide better and enhanced antihistamines.
For instance, on August 9, 2023, Novartis announced that the two Phase III trials for the antihistamine drug, remibrutinib have demonstrated clinical efficacy and met their primary endpoints in patients with chronic spontaneous urticaria. Remibrutinib is a selective Bruton’s tyrosine kinase (BTK) inhibitor. It acts by stopping histamine release by blocking the BTK cascade. The release of histamine is responsible for chronic spontaneous urticaria symptoms such as itching, hives, and swelling.
Moreover, many antihistamines are also available over-the-counter without the need for a prescription, a benefit for the patients. This accessibility makes them a convenient option for individuals experiencing mild to moderate hives. The antihistamines are also available in various formulations such as topical agents, oral tablets, and liquids.
Geographical Penetration
North America Accounted for Approximately 39.9% of the Market Share in 2022, Owing to the Strong Presence of Major Players and Advanced Healthcare Infrastructure
North America accounted for the largest market share over the forecast period owing to the presence of major players in the region and advanced healthcare infrastructure with advanced research activities. The region is home to several major pharmaceutical companies, these companies invest in the development of new drugs and therapeutics for better treatment of skin hives.
For instance, on October 18, 2022, Sanofi-aventis U.S. announced that the U.S. Food and Drug Administration has approved Allegra(R) (fexofenadine hydrochloride) oral suspension for the twice-daily treatment of symptoms associated with seasonal allergies in pediatric patients, 2 to 11 years of age, and for the treatment of chronic idiopathic urticaria in children 6 months to 11 years of age. This approval makes available a safe and effective seasonal allergy and urticaria treatment option.
Furthermore, North America is a well-known region for its well-established and advanced healthcare infrastructure including hospitals, dermatology clinics for effective treatment, and a wide range of pharmacies for urticaria drugs. This advanced healthcare infrastructure supports early detection, diagnosis, and treatment and also helps in research activities and clinical trials for therapeutic novel innovations.
Competitive Landscape
The major global players in the skin hives treatment market include Otsuka Pharmaceutical Co Ltd, Taiho Pharmaceutical, Amneal Pharmaceuticals, Galderma, F. Hoffmann-La Roche Ltd, Novartis AG, Dr. Reddy’s Laboratories, Glenmark Pharmaceuticals, Genentech, Inc., and Sanofi SA among others.
COVID-19 Impact Analysis
The COVID-19 pandemic significantly impacted the global skin hives treatment market. Many clinical trials, FDA approvals, and research activities related to the urticaria treatment are temporarily disrupted and discontinued due to the redirected focus towards COVID-related studies, impacted the market globally. Moreover, during the pandemic, non-urgent treatments are postponed due to the lockdown instructions, which leads to delayed diagnosis and treatment of skin hives.
Russia-Ukraine Conflict Analysis
The Russia-Ukraine conflict is estimated to have a moderate impact on the global skin hives treatment market. During the conflict, the import and export of raw materials and approved drugs are temporarily disrupted due to conflict issues. Many research activities and clinical trials are disrupted temporarily and due to the less presence of major players in the region, there is a moderate impact on the global market.
By Type
• Chronic Hives
• Acute Hives
By Treatment
• Anti-Inflammatory Drugs
• Anti-Itch Drugs
• Antihistamines
• Topical Steroids
• Topical Anesthetics
• Immunosuppressants
• H2 Antagonists
• Others
By Route of Administration
• Oral
• Topical
• Parenteral
By Distribution Channel
• Hospital Pharmacies
• Online Pharmacies
• Retail Pharmacies
By Region
• North America
o U.S.
o Canada
o Mexico
• Europe
o Germany
o U.K.
o France
o Spain
o Italy
o Rest of Europe
• South America
o Brazil
o Argentina
o Rest of South America
• Asia-Pacific
o China
o India
o Japan
o Australia
o Rest of Asia-Pacific
• Middle East and Africa
Key Developments
• On February 2, 2023, Amgen and AstraZeneca announced the U.S. Food and Drug Administration (FDA) has approved TEZSPIRE (tezepelumab-ekko) for self-administration in a pre-filled, single-use pen for patients aged 12 years and older with severe asthma and chronic urticaria. TEZSPIRE is also in development for other potential indications including chronic obstructive pulmonary disease, chronic rhinosinusitis with nasal polyps, chronic spontaneous urticaria, and eosinophilic esophagitis (EoE).
• On January 05, 2023, Novelty Nobility, a Korean company specializing in antibody new drug development, announced that its U.S. partner, ValenzaBio, was acquired by Acelyrin. It also announced that Novelty Nobility transferred NN2802, a pre-IND anti-c-KIT being studied as a treatment option in chronic urticaria, to ValenzaBio for a total of $733.25 million.
• On March 01, 2022, Nuvo Pharmaceuticals Inc. and Miravo Healthcare a Canadian-focused healthcare company with global reach and a diversified portfolio of commercial products, announced that its wholly owned subsidiary, Aralez Pharmaceuticals Canada Inc. has launched Blexten for pediatric use in patients 4 years of age and older. Blexten is a second-generation antihistamine drug for the symptomatic relief of allergic rhinitis and chronic spontaneous urticaria.
Why Purchase the Report?
• To visualize the global skin hives treatment market segmentation based on type, treatment, route of administration, distribution channel, and region, as well as understand key commercial assets and players.
• Identify commercial opportunities by analyzing trends and co-development.
• Excel data sheet with numerous data points of skin hives treatment market-level with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping available as excel consisting of key products of all the major players.
The global skin hives treatment market report would provide approximately 53 tables, 54 figures, and 195 Pages.
Target Audience 2023
• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies
DataM Intelligence Opinion:
According to the DataM Intelligence, the skin hives treatment market experiencing the rapid growth in recent years and is expected to grow rapidly in the coming years due to its increasing prevalence and novel therapeutic innovations for better patient outcomes. Many innovative treatment options are going to develop in the coming years by reducing the adverse effects and for effective treatment. Moreover, many clinical trials and research activities are still going on for novel therapeutics, which is expected to growth of the global skin hives treatment market in the upcoming years.